RT Journal Article
SR Electronic
T1 International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.25.22279181
DO 10.1101/2022.08.25.22279181
A1 Raad, Issam
A1 Hachem, Ray
A1 Masayuki, Nigo
A1 Datoguia, Tarcila
A1 Dagher, Hiba
A1 Jiang, Ying
A1 Subbiah, Vivek
A1 Siddiqui, Bilal
A1 Bayle, Arnaud
A1 Somer, Robert
A1 Cruz, Ana Fernández
A1 Gorak, Edward
A1 Bhinder, Arvinder
A1 Mori, Nobuyoshi
A1 Hamerschlak, Nelson
A1 Shelanski, Samuel
A1 Dragivich, Tomislav
A1 Kiat, Yee Elise Vong
A1 Fakhreddine, Suha
A1 Hanna, Pierre Abi
A1 Chemaly, Roy F.
A1 Mulanovich, Victor
A1 Adachi, Javier
A1 Borjan, Jovan
A1 Khawaja, Fareed
A1 Granwehr, Bruno
A1 John, Teny
A1 Guevara, Eduardo Yepez
A1 Torres, Harrys
A1 Ammakkanavar, Natraj Reddy
A1 Yibirin, Marcel
A1 Reyes-Gibby, Cielito C
A1 Pande, Mala
A1 Ali, Noman
A1 Rojo, Raniv Dawey
A1 Ali, Shahnoor M
A1 Deeba, Rita E
A1 Chaftari, Patrick
A1 Matsuo, Takahiro
A1 Ishikawa, Kazuhiro
A1 Hasegawa, Ryo
A1 Aguado-Noya, Ramón
A1 García-García, Álvaro
A1 Puchol, Cristina Traseira
A1 Lee, Dong-Gun
A1 Slavin, Monica
A1 Teh, Benjamin
A1 Arias, Cesar A
A1 Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team
A1 Kontoyiannis, Dimitrios P.
A1 Malek, Alexandre E.
A1 Chaftari, Anne-Marie
YR 2022
UL http://medrxiv.org/content/early/2022/08/26/2022.08.25.22279181.abstract
AB Background In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries.Methods We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers.Results We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03).Conclusions Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality.Condensed Abstract In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Cancer Institute, National Institutes of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board at MD Anderson Cancer Center and the institutional review boards of the collaborating centers. A patient waiver of informed consent was obtained. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol, statistical analysis plan, lists of deidentified individual data, generated tables and figures will be made available upon request by qualified scientific and medical researchers for legitimate research purposes. Requests should be sent to achaftari{at}mdanderson.org and yijiang{at}mdanderson.org. Data will be available on request for 6 months from the date of publication. Investigators are invited to submit study proposal requests detailing research questions and hypotheses in order to receive access to these data.